echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > European Radiology: Can gadoxetate disodium-enhanced MRI performed at different institutions, different machines, and different field strengths still reflect the correlation between liver enhancement and liver function?

    European Radiology: Can gadoxetate disodium-enhanced MRI performed at different institutions, different machines, and different field strengths still reflect the correlation between liver enhancement and liver function?

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     Gadoxetate disodium is a hepatocyte-specific contrast agent that exhibits selective hepatocyte uptake and peaks approximately 20 minutes after injection (hepatobiliary phase )
    .


    Hepatobiliary phase images improve the detection rate of primary and secondary liver tumors by enhancing the contrast difference between diseased and healthy liver tissue


     Gadoxetate disodium is a hepatocyte-specific contrast agent that exhibits selective hepatocyte uptake and peaks approximately 20 minutes after injection (hepatobiliary phase )


    Whether liver enhancement is still present on gadoxetate disodium -enhanced MRI in a multi-vendor cohort of patients with hepatocellular carcinoma collected in a prospective randomized controlled trial , published in the journal European Radiology The correlation between liver function and liver function provides a reference for further data aggregation and evaluation .
     


    In a prospective multicenter phase II trial (SORAMIC), the present study evaluated images of 359 patients undergoing standardized gadoxetate disodium -enhanced MRI scans using different scanners .
    Using univariate and multivariate analyses, liver enhancement on the hepatobiliary phase was analyzed in relation to biochemical laboratory parameters, clinical outcomes related to liver function, liver function grading systems (Child-Pugh and albumin-bilirubin [ALBI]), and scans correlation between instrument features .
     

    Significant positive correlations were found between LSR and albumin (rho = 0.


    193; p < 0.
    001) , platelet count (rho = 0.
    148; p = 0.
    004), and sodium (rho = 0.
    161; p = 0.


    Significant positive correlations were found between LSR and albumin (rho = 0.
    193; p < 0.
    001) , platelet count (rho = 0.
    148; p = 0.


    Correlation between LSR and biochemical parameters .


    Scatter plot of linear regression lines showing the relationship of LSR with statistically significant variables: (a) albumin (rho = 0.
    193, p < 0.
    001), (b) total bilirubin (rho = -0.


    Correlation between LSR and biochemical parameters .
    Scatter plot of linear regression lines showing the relationship of LSR with statistically significant variables: (a) albumin (rho = 0.
    193, p < 0.
    001), (b) total bilirubin (rho = -0.


    The present study demonstrates that enhancement on the hepatobiliary phase of gadoxetate disodium -enhanced MRI in HCC patients correlates with liver function , regardless of underlying cirrhosis, across several centers and field strengths .
    This emphasizes the importance of gadoxetate disodium -enhanced MRI as an imaging marker of liver function in the treatment decision-making process, and provides data support for the consistent assessment of patients' liver function and the wider application of liver-specific contrast agents .

    Original source:

    Original source:

    Osman Öcal,Bora Peynircioglu,Christian Loewe.


    Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.
    DOI:10.
    1007/s00330-021-08218-9

    Osman Öcal,Bora Peynircioglu,Christian Loewe.
    Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.
    DOI:10.
    1007/s00330-021-08218-9 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.